

# CURRICULUM VITAE

## Dr. med. Lorenzo Magenta

### General Information

Date of birth 09.03.1964  
Nationality: dual nationality swiss and italian  
Civil state married, 2 children

### Education

07.1984 High Scholl diploma at Liceo Classico A. Volta in Como, IT  
05.10.1995 Graduation in Medicine, Università Statale di Milano, IT  
Dissertation: "Cell-mediated immunity in chronic chagasic myocarditis. Phenotypic characterization of inflammatory infiltrates in twenty autopsies cases".  
Supervisor: Prof. A. Lazzarin, grade 110/110.  
30.11.1995 Qualification to practice as a medical surgeon, IT  
13.11.2000 Specialization in Tropical Medicine, Università degli Studi di Milano, IT  
11.08.2008 Swiss federal acknowledgement of graduation in Medicine  
14.08.2008 Swiss federal acknowledgement of specialist in tropical and travel medicine  
11.02.2009 Authorization to the practice in Canton Ticino  
02.04.2012 Federal specialization as General Practitioner

### Training and Professional Experience

11.1996 - 11.2000 • Postgraduate in Tropical Medicine, Division of Infectious Diseases, San Raffaele Hospital, Milano.  
01.2001 - 03.2005 • Resident Division of Infectious Diseases of University Hospital San Raffaele, Milano (Italy)  
11.1996 - 08.2010 • Research fellow, Infectious Diseases Unit, Department of Internal medicine, Ospedale Regionale di Lugano, Lugano  
09.2010 - 07.2013 • Resident, Center of Hepatology, Department of Internal Medicine, Clinica Luganese, Lugano  
07.2013 -01-2021 • Consultant at Ospedale La Carità, EOC, Locarno

### Current position

07.2013 – today • Vice director at Epatocentro Ticino, Lugano.  
01.2015 – today • Consultant at Clinica Luganese Moncucco, Lugano

## **Principal Areas of Expertise and Interests**

- Long-standing experience in the treatment of patients with addictions (alcohol and drugs) in the context of major related diseases (infectious and hepatopathies)
- Patients with HIV infection, therapy and management of complications
- Patients with viral hepatitis
- Patients with cirrhosis and end-stage liver disease
- Patient with liver transplantation
- Obese patients, affected by Non-Alcoholic Fatty Liver Disease (NAFLD) and non-alcoholic steatohepatitis (NASH)
- Management of complex hepatological cases (cholestatic, metabolic or autoimmune hepatopathy)
- Patients with hepatocarcinoma (HCC) and colangiocarcinoma
- Since 1996 sub-investigator or principal investigator in about 70 clinical trials in the field of antiretroviral HIV therapy, HCV therapy and NASH therapy

## **Affiliations**

- Federazione dei Medici Svizzeri (FMH)
- Ordine dei Medici del Canton Ticino (OMCT)
- Circolo Medico di Lugano (CML)
- Società Svizzera di Malattie Infettive (SSI)
- Società Svizzera di Medicina Tropicale e Parassitologia (SSTMP)
- Swiss Association for the Study of the Liver (SASL)

## **Languages**

- Italian (mother tongue)
- English (fluent)
- French (basic knowledge of written language)

## **Personal hobbies**

- Reading
- Travelling
- Photography
- Sport: alpine skiing, cross-country skiing, hiking and passion for hunting for mushroom

## Publications

1. B. Müllhaupt, D. Semela, L. Ruckstuhl, **L. Magenta**, O. Clerc, R. Torgler, F. Negro, N. Semmo. Real-world effectiveness and safety of glecaprevir/pibrentasvir therapy in patients with chronic hepatitis C virus infection in Switzerland. *Swiss Med Wkly.* 2021;151:w20399
2. N. Semmo, B. Müllhaupt, L. Ruckstuhl, **L. Magenta**, O. Clerc, R. Torgler, D. Semela. A prospective, multicenter, post-marketing observational study to measure the quality of life of HCV genotype 1 infected, treatment naïve patients suffering from fatigue and receiving 3D regimen: The HEMATITE study. *Plos One* November 4, 2020. <https://doi.org/10.1371/journal.pone.0241267>
3. A. De Gottardi, C. Fratila, R. Bertoli, A. Cerny, **L. Magenta**, P. Gianella, P. Majno-Hurst, A. Ceschi, G. Vanini, E. Bernasconi. Clinical characteristics and management of a liver transplanted patient admitted with SARS-CoV-2 infection. *Clin Res Hepatol Gastroenterol* 2020 Jun 10;S2210-7401(20)30159-5. doi: 10.1016/j.clinre.2020.05.014.
4. Bachofner J, Valli PV, Bergamin I, Kröger A, Künzler P, Baserga A, Braun DL, Seifert B, Moncsek A, Fehr J, Semela D, **Magenta L**, Müllhaupt B, Terziroli Beretta-Piccoli B, Mertens J, The Swiss Hepatitis C Cohort Study. Excellent outcome of Direct Acting Antiviral treatment for chronic hepatitis C in Switzerland. *Swiss Med Wkly.* 2018 Jan 29;148:w14560. doi: 10.4414/smw.2018.14560. eCollection 2018 Jan 29.
5. D. Semela, U. Rusch, P. Künzler, J. Mertens, B. Müllhaupt, M. Heim, N. Semmo, G. Stirnimann, J.F. Dufour, A. Baserga, **L. Magenta**, F. Negro, P. Bruggmann. Increasing imports of Direct-Acting Antivirals (DAAs) via FixHepC Buyers Club and medical tourism by Swiss patients with chronic hepatitis C infection. *Swiss Med Wkly.* 2017 ; 147 (Suppl 225)
6. J.A. Bachofner, P.V. Valli, A. Kröger, I. Bergamini, P. Kunzler, A. Baserga, D. Braun, B. Seifert, A. Moncsek, J. Fehr, D. Semela, **L. Magenta**, B. Müllhaupt, B. Terziroli Beretta-Piccoli, J.C. Mertens. Direct antiviral agent treatment of chronic hepatitis C results in rapid regression of transient elastography and fibrosis markers fibrosis-4 score and aspartate aminotransferase-platelet ratio index. *Liver Int.* 2107; 37:369-376
7. A. De Gottardi, J. Trebicka, C. Klinger, A. Plessier, S. Seijo, B. Terziroli, **L. Magenta**, D. Semela, E. Buscarini, P. Langlet, J. Görtzen, A. Puente, B. Müllhaupt, C. Navascuès, F. Nery, P. Deltenre, F. Turon, C. Engelmann, R. Arya, K. Caca, M. Peck-Radosavljevic, FWG. Leebeek, D. Valla, J.C. Garcia-Pagan; VALDIG Investigators. Antithrombotic treatment with direct-acting oral anticoagulants in patients with splanchnic vein thrombosis and cirrhosis. *Liver Int.* 2017 May;37(5):694-699. doi: 10.1111/liv.13285. Epub 2016 Nov 19.
8. A. De Gottardi, S. Seijo, A. Plessier, J. Schouten, J. Trebicka, B. Terziroli, **L. Magenta**, D. Semela, P. Langlet, F. Turon, R. Arya, M. Peck-Radosavljevic, D. Valla, J.C. Garcia-Pagan O077 : Use of direct oral anticoagulants (DOACs) in patients with splanchnic vein thrombosis and/or cirrhosis. *J Hepatol.*2015; 62, suppl 2: S229
9. L. Andreocchi, V. Toma, A. Canonica-Lepori, **L. Magenta**, S. Gyorik, L. Pellegrini, E. Bernasconi. Telaprevir-induced renal impairment: three clinical cases and a review of the literature. *Infect Dis (Lond).* 2015 Sep;47(9) :662-7
10. **L. Magenta**, R. Monotti. Epatite C. *Tribuna Medica Ticinese.* Maggio 2015;5: 119-125.
11. **L. Magenta**. HIV: complicanze a lungo termine. *Tribuna Medica Ticinese.* Novembre 2012;11: 397-402.
12. H.C. Bucher, W. Richter, T.R. Glass, **L. Magenta**, Q. Wang, M. Cavassini, P. Vernazza, B. Hirschel, R. Weber, H. Furrer, M. Battegay, E. Bernasconi. Small Dense Lipoproteins, Apolipoprotein B, and Risk of Coronary Events in HIV-Infected Patients on Antiretroviral Therapy: The Swiss HIV Cohort Study. *J Acquir Immune Defic Syndr.* 2012 June 1;60(2):135-142.
13. **L. Magenta**, S. Dell-Kuster, W.O. Richter, J. Young, R. Weber, M. Flepp, B. Hirschel, P. Vernazza, H. Furrer, M. Cavassini, L.A. Decosterd, H. Bucher, E. Bernasconi, and the Swiss HIV Cohort Study. Lipid and lipoprotein profile in HIV-infected patients treated with lopinavir/ritonavir as a component of the first combination antiretroviral therapy. *AIDS Res Hum Retroviruses.* 2011 May;27(5):525-33.

14. N.J. Mueller, C.A. Fux, B. Ledergerber, L. Elzi, P. Schmid, T. Dang, **L. Magenta**, A. Calmy, A. Vergopoulos, H.A. Bischoff-Ferrari, and the Swiss HIV Cohort Study. High prevalence of severe vitamin D deficiency in cART naïve and successfully treated Swiss HIV patients. *AIDS*, 2010 May 15;24(8):1127-34.
15. **L. Magenta**, C. Gandola, G. Robotti, C. Tosi, M. Gerbino, F. Scacchi, E. Bernasconi. Intramedullary spinal cryptococcoma in a patient with AIDS: case report and review of literature. *Shelter*, Nov 2005; issue 1: 40-47.
16. **L. Magenta**, W.O. Richter, M. Opravil, M. Flepp, H. Drechsler, P. Schmid, J.M. Evison, B. Bernasconi, E. Bernasconi. Lipoprotein pattern in HIV infected patients before starting antiretroviral therapy with lopinavir/ritonavir. *European Journal of Medical Research*, 2005 October 21, 10 (Suppl III): 5-6.
17. J.P. Zuber, A. Calmy, J.M. Evison, B. Hasse, V. Schiffer, T. Wagels, R. Nuesch, **L. Magenta**, B. Lederberger, R. Jenni, R. Speich, M. Opravil. Pulmonary arterial hypertension related to HIV infection: improved hemodynamics and survival associated with antiretroviral therapy. *Clinical Infectious Diseases*, 2004 April 15; 38: 1178-85.
18. E. Bernasconi, M. Uhr, **L. Magenta**, A. Ranno, A. Telenti and the Swiss HIV Cohort Study. Homocysteinaemia in HIV-infected patients treated with highly active antiretroviral therapy. *AIDS*, 2001 May 25; 15(8): 1081-2.
19. G. Tambussi, S. Ghezzi, S. Nozza, G. Vallanti, **L. Magenta** et al. Efficacy of low-dose intermittent subcutaneous interleukin (IL)-2 in antiviral drug-experienced human immunodeficiency virus-infected persons with detectable virus load: a controlled study of 3 IL-2 regimens with antiviral drug therapy. *J Infect Dis*. 2001 May 15; 183(10): 1476-84.
20. E. Bernasconi, **L. Magenta**, J.C. Piffaretti, A. Carota, T. Moccetti. Are nelfinavir-containing regimens effective as second-line triple therapy? *AIDS*, 2000 Jan 7; 14(1): 95-6.
21. **L. Magenta**, M. Moro, M. Guffanti, C. Uberti Foppa, M.A. Cardoso de Almeida, M. Sadigursky, A. Lazzarin, C.L. Parravicini, G. Gaiera. Ruolo dei T linfociti CD4+ e CD8+ nell'evoluzione degli infiltrati intramiocardici nella miocardiopatia chagastica cronica. *Italian Journal of Tropical medicine*, 09.05.199

## ABSTRACTS

1. N. Semmo, B. Müllhaupt, L. Ruckstuhl, **L. Magenta**, O. Clerc, R. Torgler, D. Semela. Quality of life measurement using wrist actigraphy in HCV genotype 1 infected, treatment naïve patients suffering from fatigue and receiving ombitasvir, paritaprevir and ritonavir tablets and dasabuvir tablets (Viekirax/Exviera; 3D regimen). *EASL International Liver Congress* (10-14 april 2019, Wien)
2. A. Aghemo, S. Bourgeois, M. Gschwantler, Y. Sanchez, L. Larsen, M. Bondin, **L. Magenta**, T. Asselah. Real-world health care resource utilization and quality of life with G/P treatment: a pooled analysis from post-marketing observational studies. *EASL International Liver Congress* (10-14 april 2019, Wien)
3. A. Aghemo, S. Bourgeois, M. Bondin, C. De Alvaro, L. Magenta, J. Foucher, S. Sonparote, Z.Z. Zhang, M. Gschwantler. Impact of Comorbidities and Co-medications on the Effectiveness and Safety of Glecaprevir Plus Pibrentasvir in Clinical Practice: Real-World Evidence from a Pooled Analysis of Postmarketing Observational Studies. *AASLD Liver meeting 2018* (9-13 november 2018, San Francisco)
4. D. Semela, U. Rusch, P. Künzler, J. Mertens, B. Müllhaupt, M. Heim, N. Semmo, G. Stirnimann, J.F. Dufour, A. Baserga, **L. Magenta**, F. Negro, P. Bruggmann. Increasing imports of Direct-Acting Antivirals (DAAs) via FixHepC Buyers Club and medical tourism by Swiss patients with chronic hepatitis C infection. *SASL, SSG Annual Meeting, Lausanne*, 14-15 September 2017
5. J.A. Bachofner, P.V. Valli, A. Kroeger, I. Bergamin, P. Kuenzler, A. Baserga, D. Braun, B. Seifert, A. Moncsek, J. Fehr, D. Semela, **L. Magenta** et al. Real life experience with direct antiviral agent (DAA) treatment of chronic HCV infection in three Swiss centers. *Annual meeting of the Swiss Society of Gastroenterology (SGG), Interlaken*, 22-23 September

- 2016
6. J.A. Bachofner, P.V. Valli, A. Kroeger, I. Bergamin, P. Kuenzler, A. Baserga, D. Braun, B. Seifert, A. Moncsek, J. Fehr, D. Semela, **L. Magenta** et al. DAA treatment of chronic hepatitis C results in rapid regression of transient elastography and fibrosis markers FIB-4 and APRI. Annual meeting of the Swiss Society of Gastroenterology (SGG), Interlaken, 22-23 September 2016
  7. A. Moriggia, M. Balmelli, A. Baserga, V. Gurtner, D. Hagara, **L. Magenta** et al. Hepatitis C treatment on PWUD in the DAA's era: high rate of virological response in the real life. 5<sup>th</sup> International Symposium on Hepatitis Care in Substance Users (INHSU), Oslo, 7-9 September 2016
  8. A. Moriggia, **L. Magenta** et al. High prevalence of liver fibrosis among people attending addiction clinics and rehabilitation facilities in southern Switzerland: results of two different screening programs for liver disease. 5<sup>th</sup> International Symposium on Hepatitis Care in Substance Users (INHSU), Oslo, 7-9 September 2016
  9. J.J. Feld, O. Weiland, R.T. Marinho, H. Wedemeyer, I.M. Jacobson, D.M. Jensen, T. Hassanein, V. De Ledinghen, M. Diago, **L. Magenta**, R.J. De Knegt, J.J. Xiong, E. Coakley, T. Baykal, F. Tatsch, G.R. Foster. ABT-450/r/Ombitasvir and Dasabuvir with Ribavirin Achieves High Sustained Virologic Response Rates Regardless of Baseline Characteristics: Pooled Analyses of the SAPPHIRE-I and SAPPHIRE-II Studies. IDWeek 2014 Meeting of the Infectious Diseases Society of America
  10. S.D. Shafran, S. Roberts, D. Crawford, V. de Ledinghen, S.D. Ryder, **L. Magenta** et al. SAPPHIRE-I Subpopulation Analysis: ABT-450/r/Ombitasvir (ABT-267), Dasabuvir (ABT-333), and Ribavirin Regimen Achieves High Sustained Virologic Response Rates 12 Weeks Post-treatment in Treatment-naïve Patients With Chronic HCV GT 1 Infection, Regardless of Baseline Characteristics; Oral Abstract Session; 20th International AIDS Conference, Melbourne (Australia), July 20-25, 2014
  11. J.J. Feld, O. Weiland, R.T. Marinho, H. Wedemeyer, I.M. Jacobson, D.M. Jensen, T. Hassanein, V. De Ledinghen, M. Diago, **L. Magenta**, et al. ABT-450/R/Ombitasvir and dasabuvir with ribavirin achieves high sustained virologic response rates regardless of baseline characteristics: pooled analyses of the Sapphire-I and Sapphire-II studies; Oral abstract session; ID week, Philadelphia (USA), 8-12 October 2014
  12. **L. Magenta**, E. Fossati, B. Terziroli, V. Gurtner, A. Cerny. Results of an educational and screening program for liver diseases in patients attending substance use rehabilitation programs in southern Switzerland; Second international Symposium on Hepatitis Care in Substance Users, Bruxelles 15-16 September 2011
  13. **L. Magenta**, A. Cerny, P. Antonini. Community acquired staphylococcus caprae endocarditis: case report and review of the literature. Abstract at the Reunion Annuelle Commune Societe Suisse d'Infectiologie, Societe Suisse de Medicine Tropicale et de Medicine des Voyages, Interlaken 24-25 August 2011
  14. **L. Magenta**, W.O. Richter, M. Opravil, M. Flepp, O. Keiser, H. Bucher, H. Drechsler, P. Schmid, J.M. Evison, M. Cavassini, B. Bernasconi, E. Bernasconi. Triglycerides and small, dense low-density lipoprotein in HIV infected patients treated with lopinavir/ritonavir as a component of the first combination antiretroviral therapy. Abstract n°134; Eighth International Congress on Drug Therapy in HIV Infection, Glasgow 12-16 November 2006.
  15. E. Bernasconi, **L. Magenta**, P. Vernazza, C. Bellini, P. Schmid, B. Miazza, J.C. Piffaretti, A. Cerny. Interferon alfa-2a and ribavirin "low dose" for the treatment of HCV infection in HIV co-infected patients. An open-label, pilot study. Abstract n° WB6037 XIV International AIDS Conference, Barcellona 7-12 July 2002.
  16. B. Hirschel, C. Fagard, M. Le Braz, H. Guentard, H. Hirsch, T. Wagels, **L. Magenta** et al. Granulocyte macrophage colony stimulating factor (GM-CSF) during structured treatment interruptions. Abstract n° B10470; XIV International AIDS Conference, Barcellona 7-12 July 2002.
  17. M. Cernuschi, B. Giudici, A. Tosoni, **L. Magenta** et al. Chronic diarrhea in HIV-positive patients: ultrastructural study of duodenal mucosa. Abstract n° 162; Ninth International Congress on Infectious Diseases, Buenos Aires, Argentina, April 10-13, 2000.
  18. M. Maillard, C. Uberti-Foppa, N. Gianotti, M. Cernuschi, G. Fusetti, **L. Magenta** et al.

- Increase invasive Aspergillosis among human immunodeficiency virus (HIV) infected patients. Abstract n°626; Seventh European Conference on Clinical Aspects and Treatment of HIV-infection, Lisbon, October 23-27, 1999.
19. A. Bernasconi, F. Pelloni, **L. Magenta** et al. Bowen's disease: an emerging pathology related to HIV-infection? Abstract n°684; Seventh European Conference on Clinical Aspects and Treatment of HIV-infection, Lisbon, October 23-27, 1999.
  20. E. Bernasconi, M. Uhr, M. Telenti, A. Bernasconi, **L. Magenta** et al. Homocysteinemia in HIV-1 infected patients treated with HAART. Abstract n°806; Seventh European Conference on Clinical Aspects and Treatment of HIV-infection, Lisbon, October 23-27, 1999.
  21. E. Bernasconi, **L. Magenta**, J.C. Piffaretti et al. Are nelfinavir containing regimens effective as second line triple therapy? Abstract n° 22381; 12<sup>th</sup> World AIDS Conference, Geneva, June28-July 3 1998.
  22. E. Bernasconi, A. Carota, **L. Magenta** et al. Metabolic changes in HIV-infected patients treated with protease inhibitors. Abstract n°178\*/12375; 12<sup>th</sup> World AIDS Conference, Geneva, June28-July 3 1998.
  23. **L. Magenta**, M. Moro, M. Guffanti, C. Uberti Foppa, M.A. Cardoso de Almeida, M. Sadigursky, A. Lazzarin, C. Parravicini, G. Gaiera. Ruolo di T linfociti CD4+ e CD8+ nell'evoluzione degli infiltrati infiammatori intramiocardici nella miocardiopatia chagastica cronica. Italian Journal of Tropical Medicine; Atti 2° Congresso Nazionale della Società Italiana di medicina Tropicale, 7-9 May 1998, Bardolino.
  24. L. Fumagalli, M.G. Viganò, R. Turconi, H. Hasson, **L. Magenta** et al. Impact on disease progression and survival of combined triple antiretroviral therapy and chemotherapy in HIV-positive patients with pulmonary Kaposi's sarcoma. Abstract n° 555; Sixth European Conference on Clinical Aspects and Treatment of HIV-Infection, Hamburg, October 11-15, 1997.